Adolescents with HIV do better in more prosperous African countries, even with treatment

Presenter Amy Slogrove with IAS President Linda-Gail Bekker at IAS 2017. Photo by Marcus Rose/IAS
Carole Leach-Lemens
Published: 31 July 2017

Adolescents who acquired HIV perinatally were less likely to die, grew faster and had better immune restoration on treatment if they lived in upper-middle income countries in sub-Saharan Africa, a comparative study presented at last week's 9th International AIDS Society Conference on HIV Science (IAS 2017) reported.

Of adolescents who had ever received antiretroviral therapy (ART), those in low- and lower-middle income countries had a two-and-a-half- to three-fold greater risk of death than adolescents in upper-middle income countries.

The results suggest that factors beyond the ART programme still play an important role in the health and wellbeing of adolescents with perinatally acquired HIV, Dr Amy Slogrove, presenting on behalf of the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration Adolescent Project Team said.

While global access to antiretrovirals is expanding, the emerging population of adolescents with perinatally acquired HIV continues to grow. Eighty per cent of adolescents living with perinatally or behaviourally acquired HIV live in sub-Saharan Africa. This is a complex region marked by diversity and inequality.

Expanding upon their previous analysis (presented at IAS 2016) the researchers looked at the outcomes of adolescents with perinatally acquired HIV according to country income group in sub-Saharan Africa. Their first analysis showed adolescents in sub-Saharan Africa had a two- to four-fold greater risk of death compared to adolescents in Europe, North America and South and Southeast Asia.

Through the CIPHER cohort collaboration individual retrospective data from 12 cohort networks across five continents were pooled. This analysis includes seven networks representing 25 countries in sub-Saharan Africa.

An adolescent with perinatally acquired HIV included in this analysis is defined as a child having entered care before the age of 10 with no known non-vertical route of HIV infection and having been followed after the age of 10.

Country income group was determined according to World Bank classification at the median year of the first visit by country.

Of the 30,296 adolescents included in the analysis 75.7% lived in low-income countries (LIC), close to 5% in lower-middle income countries (LMIC) and almost 20% in upper-middle income countries (UMIC). The cohort accumulated a total of 78,619 person-years of follow-up between 10 and 19 years of age.

Approximately two-thirds were born in or after 2000.

The median age at the start of ART was 8 (IQR: 6-9) years and at the last follow-up the median age was 12 (IQR: 11-14) years and was comparable in all country income groups.

Out of approximately half (15,254) of adolescents with perinatally acquired HIV with CD4 cell counts at the start of ART the median ranged from 310 (IQR: 165-520) cells/mm3 in LIC to 292 (IQR: 174-417) cells/mm3 and 318 (IQR: 162-558) cells/mm3 in LMIC and UMIC, respectively.

However, the mean CD4 cell count change between ART start and last visit was greatest in the LMIC, followed by UMIC and LIC, at 463 cells/mm3, 353 cells/mm3 and 295 cells/mm3, respectively.

Of just over half (16,181) with height-for-age Z score (HAZ) at the start of ART the median was -2.01, -2.08 and -2.02 for LIC, LMIC and UMIC, respectively (a HAZ of <-2 indicates that most of the children were already stunted at ART start).

The greatest improvement in height was seen in adolescents in UMIC followed by LIC and LMIC at 0.44, 0.16 and 0.04 mean Z-scores, respectively.

The cumulative incidence of death between the ages of 10 and 15 was similar in LIC and LMIC but lowest in UMIC, at 3.5% (95% CI: 3.1-3.8, p < 0.001) 3.9% (95%CI: 2.7-5.4) and 1.1% (95% CI: 0.8-1.4) p < 0.001, respectively,

While 85.9% (26,018) ever started ART and 12.5% (3352) started at or above 10 years of age, the differences between country income groups varied significantly.

Of the 75% (22,925) living in LIC, 83.4% (19,114) had ever started ART compared to 87.1% (1207) and 95.2% (5697) in LMIC and UMIC, p < 0.001, respectively.

More than double the number of children in LIC started ART at or above the age of 10 compared to those in UMIC and approximately 25% more compared to those in LMIC, 14.8% (2829), 6.7% (382) and 11.7% (141), p < 0.001, respectively.


Slogrove A et al. Inequality in mortality and access to antiretroviral therapy in adolescents living with perinatally-acquired HIV in sub-Saharan Africa: a Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) cohort collaboration analysis. 9th International AIDS Society Conference, Paris, abstract MOAB0203, July 2017.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Watch the webcast of this session on YouTube.

NAM's news coverage of the International AIDS Society's Conference on HIV Science has been made possible thanks to support from Gilead Sciences Europe Ltd. and Merck & Co. NAM's wider conference news reporting services have been supported by Janssen and ViiV Healthcare.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.